Contrasting of Apellis Pharmaceuticals Inc. (APLS) and OPKO Health Inc. (NASDAQ:OPK) – MS Wkly

This is therefore a comparing of the risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership in Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and OPKO Health Inc. (NASDAQ:OPK). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

Demonstrates Apellis Pharmaceuticals Inc. and OPKO Health Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 represents Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and OPKO Health Inc. (NASDAQ:OPK)s return on assets, net margins and return on equity.

Liquidity

Apellis Pharmaceuticals Inc.s Current Ratio and Quick Ratio are 15.2 and 15.2 respectively. The Current Ratio and Quick Ratio of its competitor OPKO Health Inc. are 1.1 and 1 respectively. Apellis Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to OPKO Health Inc.

Institutional & Insider Ownership

Apellis Pharmaceuticals Inc. and OPKO Health Inc. has shares owned by institutional investors as follows: 66.1% and 26.4%. Insiders owned roughly 1.6% of Apellis Pharmaceuticals Inc.s shares. Competitively, 5.5% are OPKO Health Inc.s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Apellis Pharmaceuticals Inc. had bullish trend while OPKO Health Inc. had bearish trend.

Summary

OPKO Health Inc. beats on 6 of the 10 factors Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companys Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companys pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More here:
Contrasting of Apellis Pharmaceuticals Inc. (APLS) and OPKO Health Inc. (NASDAQ:OPK) - MS Wkly